RxDoctor Payments Data

Raz Winiarsky, MD

Orthopaedic Surgery of the Spine · Brooklyn, NYNPI 1992769061

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $72,660 of the $74,554 with a category attached, or 97.5%. Royal Biologics, Inc. accounts for 97.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $68,501 and has fallen 93.3% since, to $4,622 in 2025.

$74,554in general payments, 2019–2025

Across 87 payments — averaging $856.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Royal Biologics, Inc.$73K
  • Fidia Pharma USA Inc.$342
  • Smith+Nephew$286
  • Amgen$255
  • Stryker$146
  • Vertex$126
  • plus $739 from 18 others

What the payments were for

  • Consulting fees$72,66097%
  • Food & beverage$1,8943%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,554 in reported general payments places this provider in the 75th percentile of 161 orthopaedic surgery of the spine providers in New York.

See all orthopaedic surgery of the spine providers in New York

Medicare billing

Part B allowed, 2024
$76,637
Medicare patients
131
Services billed
1,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lidocaine180$19,418
Diclofenac Sodium167$15,614
Diclofenac Epolamine27$12,963
MovantikNaloxegol Oxalate66$6,514
Enoxaparin Sodium42$3,746
Meloxicam232$831
Naproxen80$481
Cephalexin16$468
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen80$423
Ibuprofen43$357
Ondansetron Hcl75$252
Celecoxib19$136
Cyclobenzaprine Hcl21$102
Tizanidine Hcl25$68
Acetaminophen-CodeineAcetaminophen With Codeine11$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$16$6,51466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 161 orthopaedic surgery of the spine providers in New York.

Other orthopaedic surgery of the spine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →